News
In the early trading session on Monday, U.S. stocks saw Keros Therapeutics, a clinical-stage drug developer, rise by 2.1% after the company announced the initiation of a tender offer to repurchase up to $194.4 million of its own shares. This move is part of its broader $375 million capital return plan
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments